ENDRA Life Sciences Inc.
NDRA | NASDAQ
$5.97
-$0.34 (-5.39%)
Sep 22, 2026, 12:03 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | -0.51 | -0.61 | -629.88 | -1.56K | -4.43K | -2.11K |
PEG Ratio | 0.04 | -0.01 | -21.81 | 94.72 | 78.86 | 30.10 |
PS Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
PB Ratio | 1.58 | 2.74 | 1.12K | 1.91K | 4.59K | 3.51K |
P/FCF Ratio | -0.69 | -0.95 | -661.25 | -1.06K | -4.44K | -2.33K |
P/OCF Ratio | -0.69 | -0.95 | -663.60 | -1.08K | -4.45K | -2.34K |
OCF/S Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Debt / Equity Ratio | 0.22 | 0.29 | 0.07 | 0.08 | 0.07 | 0.11 |
Quick Ratio | 1.29 | 5.67 | 3.36 | 3.45 | 7 | 7.72 |
Current Ratio | 1.29 | 5.67 | 3.36 | 5 | 7.83 | 8.32 |
Asset Turnover | n/a | n/a | n/a | n/a | n/a | n/a |
Interest Coverage | n/a | n/a | n/a | -611.04 | n/a | -49.49 |
Return on Equity | -310.93% | -449.46% | -177.77% | -182.93% | -104.14% | -163.55% |
Return on Assets | -182.35% | -258.47% | -148.95% | -142.11% | -87.24% | -133.78% |
Return on Invested Capital | -178.30% | -262.95% | -173.80% | -169.75% | -99.29% | -144.88% |
Dividend Yield | n/a | 0.07% | n/a | 0% | 0% | 0% |
Payout Ratio | n/a | -0.05% | -0.01% | -0.06% | -1.08% | -3.37% |
FCF Payout Ratio | n/a | -0.07% | -0.01% | -0.06% | -0.96% | -3.06% |
Gross Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Net Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Profit Margin | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Margin | n/a | n/a | n/a | n/a | n/a | n/a |
EBITDA Margin | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove NDRA